Naxpar Group

Mumbai, India Founded: 1985 • Age: 41 yrs Listed
Pharmaceutical, cosmetic, herbal, and nutraceutical formulations are manufactured.

About Naxpar Group

Naxpar Group is a publicly listed company based in Mumbai (India) founded in 1985 by Prakash Shah and Baiju Shah. Pharmaceutical, cosmetic, herbal, and nutraceutical formulations are manufactured. It operates on a Direct-to-Consumer (D2C) and Reseller / Distribution model. Its Indian entity Parnax Lab Limited reported revenue of β‚Ή252 Cr. Naxpar Group offers products and services including Pharmaceuticals, Cosmetics, Herbal/Ayurvedic Formulations, and Nutraceuticals. Its focus areas include Pharmaceuticals and Drug Manufacturing.

Company details

Naxpar Group is involved in the development and manufacturing of finished formulations across pharmaceuticals, cosmetics, herbalAyurvedic products, and nutraceuticals. The company operates within the healthcare and personal care sectors, focusing on innovation and quality. Facilities are regularly upgraded to meet international standards, ensuring superior product offerings. Based in India, the group is recognized as a leading manufacturer in these domains, catering to both domestic and global markets with a wide range of solutions.

  • Headquarters Mumbai, India
  • Founders Prakash Shah, Baiju Shah
  • Stage Public
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website naxparlab.com
  • Social LinkedIn
  • Legal Name Parnax Lab Limited
Key Metrics
  • Market Cap
    ₹132 Cr

    PARNAXLAB · NSE

  • Share Price
    ₹116.42

    +1.66% today

  • Revenue
    ₹249 Cr

    FY 2025-26 · +32.4% YoY

  • EBITDA
    ₹25.88 Cr

    Margin 10.4%

  • Net Profit
    ₹12.80 Cr

    FY 2025-26 · +9.3% YoY

  • P/E (TTM)
    14.5x

    P/B 1.3x

  • ROE
    13.2%

    ROCE 13.0%

  • Debt / Equity
    0.85

    Interest cover 32.0x

Products & Services of Naxpar Group

Naxpar Group offers a comprehensive portfolio of products and services, including Pharmaceuticals, Cosmetics, Herbal/Ayurvedic Formulations, and Nutraceuticals.

Pharmaceuticals
Healthcare

Finished formulations in pharmaceuticals are manufactured and developed.

Cosmetics
Personal Care

Cosmetic products are produced for personal care use.

Herbal/Ayurvedic Formulations
Healthcare

Herbal and Ayurvedic formulations are developed for wellness.

Nutraceuticals
Health Supplements

Nutraceutical products are created for dietary health benefits.

Board of directors of Parnax Lab Limited (Naxpar Group)

Parnax Lab Limited is the primary company behind Naxpar Group. The board of Parnax Lab Limited currently have 6 directors; the longest-serving is Ami Mihir Shah, appointed in 2015. 16 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Ami Mihir Shah
DIN 03101049
Director31 Mar 201511 yrs 7 moParnax Lab Limited
Yogesh Kantilal Varia
DIN 09186184
Director28 May 20215 yrs 5 moParnax Lab Limited
Harish Sunderlal Panpalia
DIN 10275561
Director11 Aug 20233 yrs 3 moParnax Lab Limited
Mihir Prakash Shah
DIN 00387912
Managing Director05 Jul 20242 yrs 4 moParnax Lab Limited
Binoy Baiju Shah
DIN 00440880
Director05 Jul 20242 yrs 4 moParnax Lab Limited
Vijaykumar Shivaji Ayare
DIN 06383445
Director10 Feb 20251 yr 9 moParnax Lab Limited

People of Naxpar Group

2 people are tracked at Naxpar Group (2 in leadership).

NameRoleGroup
Co-Founder & DirectorLeadership
Co-Founder & DirectorLeadership
Premium access

Complete people profiles for Naxpar Group

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Naxpar Group

Naxpar Group is a publicly listed company on the BSE with ticker symbol PARNAXLAB in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date20 Jul 2012
  • Listed onBSE: 506128
  • Listed entityParnax Lab Limited
  • Exchange sectorHealth technology
  • ISININE383L01019
  • Share price₹162.35 (-1.61% on the day) · 2026-05-11
  • Market capitalisation₹188 Cr
  • Price to earnings14.9
  • EPS (diluted, trailing year)₹10.91
  • Volume (last session)3,005
  • Analyst consensusNo rating

Financials of Naxpar Group

Exchange-reported figures of Parnax Lab Limited, the listed company behind Naxpar Group (NSE: PARNAXLAB).

Financial Highlights

FY 2025-26 Β· Consolidated
Revenue
₹249 Cr
+32.4% YoY
EBITDA
₹25.88 Cr
-3.3% YoY
Profit After Tax
₹12.80 Cr
+9.3% YoY
Net Worth
₹95.14 Cr
+14.5% YoY
Total Assets
₹179 Cr
+16.8% YoY
Total Debt
₹82.79 Cr
+19.1% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue24918818916816390.0695.31
Revenue growth+32.4%-0.5%+12.6%+2.8%+81.0%-5.5%-
EBITDA25.8826.7723.5522.9923.039.946.43
EBITDA margin+10.4%+14.3%+12.5%+13.7%+14.1%+11.0%+6.8%
Profit before tax15.9015.6812.0612.2812.26(0.09)(1.97)
Net profit12.8011.719.608.618.23(0.38)(2.92)
Net profit margin+5.2%+6.2%+5.1%+5.1%+5.1%-0.4%-3.1%
EPS (β‚Ή)10.2710.038.377.508.40(0.43)(3.43)
Balance sheet
Total assets17915315311711891.7884.37
Net worth95.1483.1071.5862.1648.1832.5432.79
Total debt82.7969.5380.6454.7269.0858.9051.23
Cash & bank2.262.681.882.785.781.271.30
Net working capital48.2033.7240.6933.6638.5626.6324.51
Cash flow
Cash from operations8.0032.3015.8820.918.556.318.75
Cash from investing(16.39)(16.39)(31.52)(9.92)(16.50)(6.56)(13.33)
Cash from financing8.18(15.82)14.82(14.07)12.130.055.03
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue69.2656.8069.6362.9462.6053.3849.0440.22
Revenue growth (YoY)+10.6%+6.4%+42.0%+56.5%+29.5%+6.5%--
Other income0.210.151.990.970.630.180.430.19
EBITDA6.904.304.665.718.087.446.634.28
EBITDA margin+10.0%+7.6%+6.7%+9.1%+12.9%+13.9%+13.5%+10.6%
Depreciation2.332.222.041.962.101.941.831.79
Interest1.601.641.611.471.401.221.281.23
Profit before tax3.180.593.003.255.214.463.951.45
Tax0.990.170.810.541.581.181.030.24
Net profit2.190.422.192.713.633.282.921.21
EPS (β‚Ή)1.900.371.902.373.152.852.551.06
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue6.637.027.447.477.152.377.68
Revenue growth-5.6%-5.7%-0.4%+4.5%+201.7%-69.1%-
EBITDA(1.62)1.242.091.561.37(0.45)0.55
EBITDA margin-24.4%+17.7%+28.1%+20.9%+19.2%-19.0%+7.2%
Profit before tax0.661.872.431.610.78(1.25)(0.45)
Net profit0.931.411.811.190.54(1.13)(1.99)
Net profit margin+14.0%+20.1%+24.3%+15.9%+7.6%-47.7%-25.9%
EPS (β‚Ή)0.771.211.591.050.55(1.33)(2.36)
Balance sheet
Total assets23.4522.5721.1820.4421.9516.1416.90
Net worth23.4222.5521.1619.3612.754.715.82
Total debt0.000.000.001.079.2011.4111.06
Cash & bank1.101.280.461.284.350.110.12
Net working capital10.838.966.965.576.584.185.18
Cash flow
Cash from operations(0.72)0.280.08(0.28)(0.36)0.472.20
Cash from investing0.57(0.19)0.300.140.000.00(0.01)
Cash from financing(0.03)(0.02)(1.21)(2.92)4.59(0.48)(1.55)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue0.532.570.252.711.701.970.840.99
Revenue growth (YoY)-68.8%+30.5%-70.2%+173.7%+10.4%-46.2%--
Other income0.200.211.760.220.200.190.190.17
Total expenses0.861.913.271.961.201.811.120.92
EBITDA(0.33)0.66(3.02)0.750.500.16(0.28)0.07
EBITDA margin-62.3%+25.7%-1208.0%+27.7%+29.4%+8.1%-33.3%+7.1%
Depreciation0.020.020.020.020.020.020.020.02
Interest0.000.000.010.000.020.010.010.01
Profit before tax(0.15)0.85(1.29)0.950.660.32(0.12)0.21
Tax0.110.00(0.73)0.240.170.08(0.03)0.05

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 18 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue69.2656.8069.6362.9462.6053.3849.0440.22
Revenue growth (YoY)+10.6%+6.4%+42.0%+56.5%+29.5%+6.5%--
Other income0.210.151.990.970.630.180.430.19
EBITDA6.904.304.665.718.087.446.634.28
EBITDA margin+10.0%+7.6%+6.7%+9.1%+12.9%+13.9%+13.5%+10.6%
Depreciation2.332.222.041.962.101.941.831.79
Interest1.601.641.611.471.401.221.281.23
Profit before tax3.180.593.003.255.214.463.951.45
Tax0.990.170.810.541.581.181.030.24
Net profit2.190.422.192.713.633.282.921.21
EPS (β‚Ή)1.900.371.902.373.152.852.551.06
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue24918818916816390.0695.31
Revenue growth+32.4%-0.5%+12.6%+2.8%+81.0%-5.5%-
Other income3.781.680.820.770.330.210.66
Total expenses22316116514514080.1288.88
Employee cost0.0024.4323.7220.0517.4313.6814.08
EBITDA25.8826.7723.5522.9923.039.946.43
EBITDA margin+10.4%+14.3%+12.5%+13.7%+14.1%+11.0%+6.8%
Depreciation8.057.386.966.535.875.164.46
Interest5.715.395.354.955.235.084.60
Profit before tax15.9015.6812.0612.2812.26(0.09)(1.97)
Tax4.104.142.423.654.010.280.95
Net profit12.8011.719.608.618.23(0.38)(2.92)
Net profit margin+5.2%+6.2%+5.1%+5.1%+5.1%-0.4%-3.1%
EPS (β‚Ή)10.2710.038.377.508.40(0.43)(3.43)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital11.4911.4911.4911.499.818.508.50
Reserves & surplus83.6571.6160.0950.6736.5524.0424.29
Shareholders' funds (net worth)95.1483.1071.5862.1648.1832.5432.79
Minority interest0.160.140.120.110.090.080.07
Secured loans45.5828.5238.8522.7227.4821.5429.65
Unsecured loans37.2141.0141.7932.0041.6037.3621.58
Total debt82.7969.5380.6454.7269.0858.9051.23
Total liabilities17915315311711891.7884.37
Assets
Gross block16112912710897.2579.4072.73
Net block11588.2689.4876.8071.9559.6757.68
Capital work in progress11.2929.4420.612.333.344.912.91
Investments0.160.160.160.160.220.220.22
Inventories36.2225.7729.9321.6919.9310.7911.15
Sundry debtors37.8130.7632.5627.8938.0816.7123.08
Cash & bank balances2.262.681.882.785.781.271.30
Loans & advances14.395.568.944.967.2410.4710.08
Total current assets90.6864.7773.3157.3271.0339.2445.61
Total current liabilities42.4831.0532.6223.6632.4712.6121.10
Net working capital48.2033.7240.6933.6638.5626.6324.51
Total assets17915315311711891.7884.37
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.550.461.284.360.180.39(0.05)
Net cash from operating activities8.0032.3015.8820.918.556.318.75
Net cash from investing activities(16.39)(16.39)(31.52)(9.92)(16.50)(6.56)(13.33)
Net cash from financing activities8.18(15.82)14.82(14.07)12.130.055.03
Net change in cash(0.21)0.09(0.82)(3.08)4.18(0.21)0.44
Closing cash2.262.681.882.785.781.271.30
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+32.4%-0.5%+12.6%+2.8%+81.0%-5.5%-
EBITDA growth-3.3%+13.7%+2.4%-0.2%+131.7%+54.6%-
PBT growth+1.3%+30.0%-1.8%+0.2%+9998.0%+95.4%-
Net income growth+9.3%+22.0%+11.5%+4.6%+2265.8%+87.0%-
Revenue CAGR (3Y)+14.0%+4.8%+28.0%+20.7%+14.4%-5.1%+0.2%
EBITDA CAGR (3Y)+4.0%+5.1%+33.3%+52.9%+31.1%+0.2%-21.0%
Profitability & leverage
Net income margin+4.7%+6.2%+5.1%+5.2%+5.1%-0.4%-3.1%
Return on capital employed+13.0%+13.8%+12.9%+14.7%+16.7%+5.7%+3.2%
Return on net worth+13.2%+14.9%+14.4%+15.6%+20.5%-1.1%-8.5%
Debt / equity0.850.971.011.121.591.691.36
Long-term debt / equity0.310.360.340.330.470.570.53
Interest cover32.0427.8032.2530.0730.48106.28233.50
Efficiency & per share
Fixed asset turnover1.711.471.611.631.851.181.42
Inventory turnover8.026.747.318.0510.618.219.72
Debtors turnover7.255.936.245.085.954.534.51
EPS (β‚Ή)10.2510.038.377.508.40(0.43)(3.43)
Dividend per share (β‚Ή)0.000.000.000.000.000.000.00
Book value per share (β‚Ή)82.8372.3562.3254.1147.2438.2638.56
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue0.532.570.252.711.701.970.840.99
Revenue growth (YoY)-68.8%+30.5%-70.2%+173.7%+10.4%-46.2%--
Other income0.200.211.760.220.200.190.190.17
Total expenses0.861.913.271.961.201.811.120.92
EBITDA(0.33)0.66(3.02)0.750.500.16(0.28)0.07
EBITDA margin-62.3%+25.7%-1208.0%+27.7%+29.4%+8.1%-33.3%+7.1%
Depreciation0.020.020.020.020.020.020.020.02
Interest0.000.000.010.000.020.010.010.01
Profit before tax(0.15)0.85(1.29)0.950.660.32(0.12)0.21
Tax0.110.00(0.73)0.240.170.08(0.03)0.05
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue6.637.027.447.477.152.377.68
Revenue growth-5.6%-5.7%-0.4%+4.5%+201.7%-69.1%-
Other income2.370.710.540.370.160.070.42
Total expenses8.255.785.355.915.782.827.13
Employee cost0.000.900.740.550.520.450.51
EBITDA(1.62)1.242.091.561.37(0.45)0.55
EBITDA margin-24.4%+17.7%+28.1%+20.9%+19.2%-19.0%+7.2%
Depreciation0.060.060.060.070.040.040.04
Interest0.030.020.140.250.710.831.38
Profit before tax0.661.872.431.610.78(1.25)(0.45)
Tax(0.24)0.460.620.420.24(0.12)1.53
Net profit0.931.411.811.190.54(1.13)(1.99)
Net profit margin+14.0%+20.1%+24.3%+15.9%+7.6%-47.7%-25.9%
EPS (β‚Ή)0.771.211.591.050.55(1.33)(2.36)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital11.4911.4911.4911.499.818.508.50
Reserves & surplus11.9311.069.677.871.12(3.79)(2.68)
Shareholders' funds (net worth)23.4222.5521.1619.3612.754.715.82
Secured loans0.000.000.001.071.892.632.77
Unsecured loans0.000.000.000.007.318.788.29
Total debt0.000.000.001.079.2011.4111.06
Total liabilities23.4522.5721.1820.4421.9516.1416.90
Assets
Gross block1.081.051.050.920.870.870.87
Net block0.390.430.490.430.440.480.53
Capital work in progress0.000.000.000.000.000.000.00
Investments10.0310.0310.0310.0310.0710.0710.07
Inventories0.800.780.900.580.790.580.15
Sundry debtors0.420.850.591.081.860.432.06
Cash & bank balances1.101.280.461.284.350.110.12
Loans & advances9.517.796.083.561.164.564.60
Total current assets11.8310.708.036.508.165.686.93
Total current liabilities1.001.741.070.931.581.501.75
Net working capital10.838.966.965.576.584.185.18
Total assets23.4522.5721.1820.4421.9516.1416.90
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.500.441.274.330.100.11(0.53)
Net cash from operating activities(0.72)0.280.08(0.28)(0.36)0.472.20
Net cash from investing activities0.57(0.19)0.300.140.000.00(0.01)
Net cash from financing activities(0.03)(0.02)(1.21)(2.92)4.59(0.48)(1.55)
Net change in cash(0.18)0.06(0.83)(3.07)4.23(0.01)0.64
Closing cash1.101.280.461.284.350.110.12
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-5.6%-5.7%-0.4%+4.5%+201.7%-69.1%-
EBITDA growth-230.7%-40.7%+34.0%+13.9%+404.4%-181.8%-
PBT growth-64.9%-22.6%+50.9%+106.4%+9998.0%-177.8%+13.5%
Net income growth-34.0%-22.1%+52.1%+120.4%+147.8%+43.2%-
Revenue CAGR (3Y)-3.9%-0.6%+46.4%-0.9%+3.3%-25.8%+13.3%
EBITDA CAGR (3Y)--3.0%-+41.6%+139.3%-26.0%-4.9%
Profitability & leverage
Net income margin+13.6%+20.2%+24.3%+15.9%+7.6%-47.7%-25.8%
Return on capital employed+2.4%+6.7%+9.1%+6.2%+6.2%0.0%0.0%
Return on net worth+3.2%+5.0%+6.5%+4.8%+4.0%0.0%0.0%
Debt / equity0.000.000.030.321.182.131.63
Long-term debt / equity0.000.000.000.040.170.440.42
Interest cover-1.791.686.9016.7853.38-169.39270.59
Efficiency & per share
Fixed asset turnover6.236.697.558.358.222.728.83
Inventory turnover8.398.3610.0510.9110.446.4926.95
Debtors turnover10.449.758.915.086.241.903.37
EPS (β‚Ή)0.771.211.591.050.55(1.33)(2.36)
Dividend per share (β‚Ή)0.000.000.000.000.000.000.00
Book value per share (β‚Ή)20.3919.6318.4216.8511.145.546.85

Web traffic of Naxpar Group

Websites that share an audience with Naxpar Group (naxparlab.com).

Similar websites

Websites whose visitors overlap most with Naxpar Group. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
google.co.in
100%
77M#407View details
mangalamdrugs.com
95%
9.9K#1,747,627View details
salvuspharma.in
salvuspharma.in
91%
#1,994,124–
astermedipharm.in
astermedipharm.in
90%
#9,642,018–
calyxindia.com
87%
1K#7,901,342View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 16 similar websites and full traffic analytics for Naxpar Group

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 16 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Naxpar Group (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 72.52 M1,115
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M4,050
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.44 B19,801
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Naxpar Group

Premium access

Complete news archive for Naxpar Group

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Naxpar Group

Naxpar Group was founded in 1985.

Naxpar Group is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

The primary company behind Naxpar Group, Parnax Lab Limited, reported revenue of β‚Ή252 Cr for FY 2026, up 32% year on year.

Naxpar Group is involved in the development and manufacturing of finished formulations across pharmaceuticals, cosmetics, herbalAyurvedic products, and nutraceuticals. The company operates within the healthcare and personal care sectors, focusing on innovation and quality. Facilities are regularly upgraded to meet international standards, ensuring superior product offerings. Based in India, the group is recognized as a leading manufacturer in these domains, catering to both domestic and global markets with a wide range of solutions.

Naxpar Group offers Pharmaceuticals, Cosmetics, Herbal/Ayurvedic Formulations, and Nutraceuticals.

Yes, Naxpar Group is publicly traded on BSE under the ticker symbol PARNAXLAB.

Naxpar Group operates through Parnax Lab Limited.

The legal entities of Naxpar Group currently have 7 directors, including Ami Mihir Shah, Yogesh Kantilal Varia, Preet Vijay Kukreja and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available